Clinical Trials Directory

A Phase II Study Of hu14.18-IL2 In Children With Recurrent Or Refractory Neuroblastoma

RATIONALE: Biological therapies such as hu14.18-interleukin-2 fusion protein work in different ways to stimulate the immune system and stop tumor cells from growing. PURPOSE: This phase II trial is studying how well hu14.18-interleukin-2 fusion protein works in treating young patients with recurrent or refractory neuroblastoma.

Stanford is not currently accepting new patients for this trial. You may want to check to see if other locations are recruiting.



  • biological : hu14.18-Interleukin-2 fusion protein

Phase: Phase 2


Ages Eligible For Study:

N/A - 21 Years

External Links

Explore related trials

Contact information

Primary Contact:

LPCH New Patient Coordinator 6507251072

Stanford University School of Medicine 300 Pasteur Drive Stanford, CA 94305

Stanford Medicine Resources:

Footer Links: